News

The U.S. Food and Drug Administration (FDA) approved the use of lumacaftor/ivacaftor (Orkambi^®) today for children with cystic fibrosis ages 6 to 11, who have two copies of the F508del mutation.

The U.S. Food and Drug Administration (FDA) has decided not to approve the use of ivacaftor (Kalydeco^®) to treat people with cystic fibrosis ages 2 and older who have one of 23 rare CF mutations, known as “residual function” mutations.